Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CG Oncology, Inc. (NASDAQ: CGON) SEC filings page provides access to the company’s official U.S. Securities and Exchange Commission disclosures related to its late-stage clinical biopharmaceutical activities in non-muscle invasive bladder cancer (NMIBC). As a public company, CG Oncology files periodic and current reports that describe its financial condition, governance changes, and key clinical and regulatory milestones for its investigational intravesical oncolytic immunotherapy, cretostimogene grenadenorepvec.
Among the most relevant documents for CGON are current reports on Form 8-K, which the company uses to report material events. Recent 8-K filings have detailed board of director changes, including the appointment of a new director and the resignation of another, as well as transitions in the principal financial and accounting officer role. Other 8-Ks reference press releases announcing quarterly financial results, updated BOND-003 Cohort C data in high-risk BCG-unresponsive NMIBC, and corporate presentations at healthcare conferences.
Investors also look to CG Oncology’s quarterly and annual reports (Forms 10-Q and 10-K, when available) for broader context on its clinical development program, including the BOND-003 and PIVOT-006 Phase 3 trials and the CORE-008 Phase 2 study, as well as information about its Expanded Access Program in North America. These filings typically discuss risk factors, research and development expenses, and other elements that shape the company’s outlook as a late-stage clinical biopharmaceutical issuer.
On Stock Titan, CGON filings are updated as they are posted to EDGAR, and AI-powered tools can help summarize lengthy documents such as earnings-related 8-K exhibits or future 10-K and 10-Q reports. Users can also review governance and compensation disclosures embedded in 8-K items related to director appointments and executive transitions, and track how these developments align with CG Oncology’s efforts to advance cretostimogene through the regulatory process.
CG Oncology, Inc. filed an amendment to its prospectus to increase its at-the-market common stock offering under a sales agreement with Jefferies LLC to an aggregate offering price of up to $550,000,000. The amendment updates a prior prospectus that covered up to $250,000,000 of common stock under the same agreement. CG Oncology has already sold 5,861,984 shares for gross proceeds of $250,000,000 under this program, and the amendment adds up to an additional $300,000,000 of common stock capacity.
CG Oncology is updating its at-the-market equity program so it may sell up to $550.0 million of common stock through Jefferies under an existing sales agreement. The company has already sold 5,861,984 shares for gross proceeds of $250.0 million and is increasing the capacity by an additional $300.0 million. At a recent share price of $53.72, the amendment illustrates sales of 10,238,273 shares to raise about $550.0 million, which would raise net tangible book value per share from $8.60 to $13.62 as of September 30, 2025. New investors buying at that assumed price would face immediate dilution of $40.10 per share, and future option exercises or additional equity financings could further dilute existing holders.
CG Oncology director James Mulay reported option exercises and share sales for CG Oncology, Inc. common stock on January 9, 2026. He exercised a director stock option for 654 shares at an exercise price of
CGON filed a notice of proposed sale of restricted or control securities. The filing covers the planned sale of 13,109 common shares, with an aggregate market value of $549,660.37, through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/09/2026. The issuer had 80,666,179 common shares outstanding. The shares to be sold were acquired on 01/09/2026 by exercising stock options granted by the issuer, paid for in cash on the same date.
CG Oncology reported new clinical timing and data for its bladder cancer programs. The company now expects topline Phase 3 PIVOT-006 data in the first half of 2026 for intermediate-risk non–muscle invasive bladder cancer, a U.S. population estimated at over 50,000 patients. Updated BOND-003 Cohort P results for cretostimogene monotherapy in BCG-unresponsive papillary-only disease showed Kaplan-Meier high-grade event-free survival of 95.7%, 84.6% and 80.4% at 3, 6 and 9 months in 51 evaluable patients, with no Grade 3 or higher treatment-related adverse events, no radical cystectomies and no progression to muscle-invasive disease. First results from CORE-008 Cohort A in high-risk, BCG-naïve patients with CIS showed an overall complete response rate of 83.7% (41 of 49), including 79.2% with the original administration and 88.0% with an optimized two-step administration, with mostly low-grade, bladder-localized adverse events and no related serious or Grade 3+ events.
CG Oncology, Inc. (CGON) disclosed a new stock option grant to a director. On 11/24/2025, the reporting person received a director stock option to purchase 20,889 shares of CG Oncology common stock at an exercise price of $43.56 per share. The option expires on 11/23/2035 if not exercised.
According to the vesting terms, 1/36th of the shares subject to the option vest monthly following November 24, 2025, as long as the director continues to provide service to the company through each vesting date. After this grant, the reporting person beneficially owns 20,889 derivative securities directly in the form of these stock options.
CG Oncology, Inc. (CGON) director Christina Rossi has filed an initial insider ownership report indicating that she currently beneficially owns no securities of the company. Both the non-derivative and derivative security tables show no holdings, and the explanation section explicitly states that no securities are beneficially owned.
CG Oncology, Inc. appointed Christina Rossi to its Board of Directors, effective November 24, 2025, as a Class II director with a term running until the 2026 annual meeting of stockholders. Her compensation follows the company’s standard non-employee director program, including an annual cash fee of $45,000, paid quarterly, and an initial grant of 20,889 stock options that vest in equal monthly installments over three years, contingent on her continued service.
The company also reported that Simone Song resigned from the Board and all committees on November 22, 2025, effective immediately. The company stated that her resignation was not due to any disagreement with CG Oncology. Ms. Song had been a member of the Audit Committee and chair of the Compensation Committee.
CG Oncology, Inc. (CGON) filed a Form 3 reporting that its Interim Principal Financial and Accounting Officer, James M. DeTore, currently holds no beneficial ownership of the company’s securities. The filing identifies him as an officer of CG Oncology and confirms that no non-derivative or derivative securities are reported as beneficially owned. The Form 3 is filed by a single reporting person and serves as an initial ownership statement required under securities regulations.
CG Oncology, Inc. (CGON) director Leonard Post reported a small insider transaction involving company stock. On 11/17/2025, he exercised a director stock option to acquire 1,000 shares of common stock at an exercise price of $0.6 per share, then sold those 1,000 shares of common stock at a price of $41.43 per share. After these transactions, he reported owning 0 shares of common stock directly.
Following the option exercise, he continued to hold 117,077 derivative securities in the form of stock options, which are exercisable until 07/08/2028 and are fully vested. The filing notes that the sale was carried out under a Rule 10b5-1 trading plan that Leonard Post adopted on September 6, 2024, indicating the trades were pre-arranged under that plan.
FAQ
What is the current stock price of CG Oncology (CGON)?
What is the market cap of CG Oncology (CGON)?
